Skip to main content

Sources last read

Alcohol · trial evidence

GLP-1s and alcohol

Three randomized trials found that semaglutide changed some alcohol-use outcomes. It is not FDA-approved for alcohol use disorder, and these trials do not answer how much alcohol is safe for one person.

Source: three randomized trials and current FDA labels, read 2026-08-16

What matters first

Randomized trials
3
Drug studied
Semaglutide
FDA-approved for alcohol use disorder
No
A personal drinking limit
Not established by these trials

There are two questions hiding inside “GLP-1s and alcohol.” One is about drinking while taking a prescribed drug. The other is whether a GLP-1 drug can treat alcohol use disorder. The studies below tested the second question. They do not set a personal drinking limit or replace advice from the clinician who knows a person’s medicines and health history.

The boundary

Semaglutide is not FDA-approved to treat alcohol use disorder. These trials are treatment research, not a dosing guide or a reason to change prescribed care.

All three rows here studied semaglutide. A search for Zepbound or Mounjaro names tirzepatide, which is a different molecule. These results should not be silently carried from one to the other.

Tirzepatide · do not merge the evidence

What the tirzepatide record actually contains

Search results put three kinds of evidence side by side. One is a human report. One comes from animals. One is an unfinished trial. None is a randomized result in people.

human observation

153 people reported their own drinking

All had obesity. Those taking semaglutide or tirzepatide reported drinking less than before treatment and less than the control group.

The study mixed both drugs and relied on self-report. It did not assign people at random, so it cannot prove a tirzepatide effect.

rodent experiment

Tirzepatide changed drinking in animals

Tirzepatide reduced alcohol use and relapse-like behavior in mouse and rat tests.

These were animals, not people. The result cannot set a safe amount or show that tirzepatide treats alcohol use disorder.

human trial with no results

A 42-person trial is recruiting

The phase 2 trial compares weekly tirzepatide with placebo in adults with alcohol use disorder and excess weight. It has no results.

A registry shows what researchers plan to test. It does not show whether the drug works or what harms may emerge.

Three trials, three different questions

The table keeps the primary outcome beside the result that did not move. That matters: a positive secondary outcome does not turn a missed primary outcome into a win.

Randomized semaglutide trials that measured alcohol use or craving
StudyPeople and treatmentPrimary outcomeWhat changedWhat did not
9-week injection trialPMID 39937469 · NCT0552077548 non-treatment-seeking adults with alcohol use disorder. 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, then 1 mg for 1 week.laboratory alcohol self-administration after treatmentSemaglutide reduced alcohol consumed in the laboratory task and reduced drinks per drinking day and weekly craving.It did not reduce average drinks per day or the number of drinking days in this small trial.
8-week oral trialPMID 4252206550 treatment-seeking adults with moderate to severe alcohol use disorder. 3 mg daily for 4 weeks, then 7 mg daily for 4 weeks.laboratory cue-elicited craving at week 6Semaglutide reduced heavy drinking days, drinks per drinking day and naturalistic craving among secondary outcomes.It did not significantly improve the primary outcome of laboratory craving or reduce drinks per day.
26-week obesity and AUD trialPMID 42070571 · NCT05895643108 treatment-seeking adults with alcohol use disorder and comorbid obesity. 2.4 mg weekly plus standard cognitive behavioral therapy.change in heavy drinking days after 26 weeksHeavy drinking days fell 13.7 percentage points more with semaglutide than with placebo in the trial’s estimated treatment difference.The single-center trial studied people with both obesity and alcohol use disorder, so it did not establish the same result for every person who drinks.

What the studies found

What moved

Some drinking and craving outcomes

Each trial reported at least one alcohol outcome that favored semaglutide. The longest trial reported fewer heavy drinking days than placebo after 26 weeks.

What remains open

Approval, general use and personal safety

The trials differed in route, dose, length and population. They do not establish an AUD label, a safe amount to drink, or the same effect for every GLP-1 drug.

Follow the molecule, label or safety record

Semaglutide evidence guideWhat the molecule is and which human results sit behind it.Semaglutide side effectsThe reported reactions and the source behind each one.Wegovy label scheduleThe approved product schedule, separate from research dosing.Tirzepatide evidence guideThe molecule behind Zepbound and Mounjaro, kept separate from semaglutide.Tirzepatide side effectsThe label and human-study safety record for the molecule readers are asking about.How this page is sourcedThe source labels, review dates and correction rules.

Review boundary

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer

Reviewed 2026-08-16

The cited trials show what researchers measured. They do not support using semaglutide for alcohol use, set a drinking limit or decide whether alcohol is safe with a person’s other medicines. Those are clinical decisions.

Questions readers ask

Can you drink alcohol if taking tirzepatide?

No study sets a safe amount for one person. The evidence covers drinking outcomes, not a personalized interaction limit.

What happens if you drink alcohol on GLP-1?

No study gives one answer for every person. Semaglutide trials measured craving and drinking; randomized tirzepatide results are not available.

Can tirzepatide help with drinking alcohol?

Nobody has published randomized human results yet. One self-report study grouped it with semaglutide, rodent work was positive, and trials are underway.

What not to do while on tirzepatide?

This evidence cannot become a personal restriction list. The approved label and prescriber are the sources for treatment instructions.

8primary sources, each with the day we read it — open the documents used on this page